超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

人福醫藥
人福醫藥集團股份公司（以下簡稱“人福醫藥”）于1993年3月30日成立，于1997年6月6日在上海證券交易所上市（股票代碼：600079.SH）。人福醫藥是湖北省第一家上市的民營高科技企業，也是武漢東湖新技術開發區第一家上市公司。經過近20年的發展，人福醫藥已成為綜合性的醫藥產業集團，下轄10多家醫藥生產企業和多家醫藥商業企業是湖北省內生產能力最強、劑型最全、品種最多、資源最雄厚的醫藥企業，已成為湖北省醫藥工業的龍頭企業、中國制藥工業百強企業、國家級企業技術中心，是資本市場上最受認可和最具投資價值的醫藥類上市公司之一。

作為“國家級企業技術中心”、“國家重大新藥創制專項的承擔單位”，公司堅持以研發為先導，持續進行研發投入，與國內外著名研發機構建立了緊密聯系和合作平臺，并與中國軍事醫學科學院合作成立了"軍科光谷創新藥物研發中心"。人福醫藥堅持做醫藥領域"細分市場領導者"的戰略，已在國內的麻醉藥、生育調節藥、維吾爾藥等領域建立了領導地位，并正在生物制品、基因工程藥等多個細分領域培養自身的特有競爭力；同時，打造醫藥區域商業龍頭企業，實現工商良性互動。人福醫藥正積極融入國際市場，建立世界級的全球經營的制藥公司，力爭成為歐美等國際主流市場仿制藥的主流供應商。

人福醫藥將由"細分市場"的"強"成就"醫藥市場"的“大”，目標是十二五期間內實現年銷售收入過百億，進入中國醫藥工業前20名，成為中國醫藥行業的領導者之一！

人福醫藥產業園
位于武漢光谷生物城，占地面積約500畝，整個產業園包括：中樞神經用藥生產基地、生育調節用藥生產基地、健康護理生產基地、藥品出口生產基地（一、二期）、生物制品生產基地、基因工程藥物生產基地等8個項目。總投資20億元，建成后將實現年銷售收入50億元，利稅10億元。

Humanwell Healthcare Group (Humanwell) Co., Ltd. was founded in 1993 and listed in Shanghai Stock Exchange in 1997 (stock code:600079.SH). It was the first listed high-tech private enterprise from Hubei Province and the first listed enterprise from East Lake High-tech Development Zone in Wuhan. After nearly 20 years of development，Humanwell has become an integrated healthcare group with more than 18 pharmaceutical manufacturing subsidiaries and 14 pharmaceutical distribution companies. Our total asset stands at over 7.8 billion RMB.
Humanwell has won honors such as “National Level Enterprise Technology Center”, “Contractor of National Key Innovative Drug Development Projects”, “Top 100 of China Pharmaceutical Manufacturing Company”, the “No.1 Pharmaceutical Manufacturing Enterprises” in Hubei province, and one of best pharmaceutical distribution firms in Hubei province. Humanwell is also regarded as one of the most valuable and promising pharmaceutical groups in the public capital markets. In last two years, Humanwell achieved operating revenue of 3.6 and 5.3 billion RMB, and net profit of 300 and 400 million RMB, respectively. From 2006 to 2012, Humanwell’s operating revenue has grown at annual rate of 38.6%, double that of industry average.
We aim to achieve operating revenue of 7 billion RMB in 2013 and 10 billion RMB by 2015, through both organic growth and external expansion. We are poised to be one of the leading Chinese pharmaceutical companies in asset quality, profitability, and growth potential.